Search

Your search keyword '"Veronika Logovinsky"' showing total 18 results
Start Over Author "Veronika Logovinsky" Journal alzheimer's & dementia
18 results on '"Veronika Logovinsky"'

1. P1‐361: ASSESSING FUNCTION IN EARLY AD: ANALYSIS OF ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) 3 DATA FOR THE FINANCIAL CAPACITY INSTRUMENT SHORT FORM (FCI‐SF)

Author

Chad J. Swanson, Yong Zhang, Emily J. Mayo, and Veronika Logovinsky

Subjects
Gerontology, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, media_common.quotation_subject, Neurology (clinical), Geriatrics and Gerontology, Function (engineering), Psychology, Alzheimer's Disease Neuroimaging Initiative, media_common
Published
2018
Full Text
View/download PDF

2. [P2–055]: PHARMACOLOGICAL CHARACTERIZATION OF BAN2401‐MEDIATED Aβ PROTOFIBRIL CLEARANCE BY MICROGLIA

Author

Lars Lannfelt, Malin Johannesson, Chad J. Swanson, Veronika Logovinsky, Andrew Satlin, Christer Möller, and Linda Söderberg

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, medicine.anatomical_structure, Developmental Neuroscience, Microglia, Epidemiology, Chemistry, Health Policy, Immunology, medicine, Neurology (clinical), Geriatrics and Gerontology, Cell biology
Published
2017
Full Text
View/download PDF

3. [P1–070]: THE FINANCIAL CAPACITY INSTRUMENT–SHORT FORM IS A NOVEL, PERFORMANCE‐BASED MEASURE THAT MAY HELP DIFFERENTIATE MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER's DISEASE POPULATIONS IN CLINICAL TRIALS

Author

Veronika Logovinsky, Adam Gerstenecker, Chad J. Swanson, Tarrant McPherson, and Daniel C. Marson

Subjects
medicine.medical_specialty, Epidemiology, Health Policy, 05 social sciences, Measure (physics), 050109 social psychology, Disease, Clinical trial, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Mild dementia, medicine, 0501 psychology and cognitive sciences, Neurology (clinical), Geriatrics and Gerontology, Psychology, Cognitive impairment, Psychiatry, 050104 developmental & child psychology
Published
2017
Full Text
View/download PDF

4. P4‐310: Composite measures in Alzheimer's disease clinical trials: How an in‐study data quality program ensures immediate and ongoing quality of the sum of their parts

Author

Chad J. Swanson, Antonio Hernandez, David Miller, Veronika Logovinsky, and Samantha Bellitz

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, media_common.quotation_subject, Disease, Clinical trial, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Data quality, Medicine, Quality (business), Neurology (clinical), Geriatrics and Gerontology, business, Intensive care medicine, media_common
Published
2015
Full Text
View/download PDF

5. F4‐03‐03: VALIDATION OF NOVEL COMPOSITE OUTCOME MEASURES FOR PRE‐DEMENTIA ALZHEIMER'S DISEASE

Author

Tobias Verbeke, Alette M. Wessels, Michael T. Ropacki, Peng Yu, Nandini Raghavan, Jinping Wang, Gerald Novak, Peter Castelluccio, Veronika Logovinsky, Enchi Liu, Xin Zhao, and David M. Shera

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Composite outcomes, Disease, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Physical medicine and rehabilitation, Developmental Neuroscience, medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, business
Published
2014
Full Text
View/download PDF

6. P3‐404: CONSIDERATION FOR 'EARLY ALZHEIMER'S DISEASE (AD)' TRIALS WITH A SINGLE PRODROMAL AD AND MILD AD DEMENTIA POPULATION: ADNI DATA ANALYSIS AND INITIAL OBSERVATIONS FROM THE BAN2401‐G000‐201 TRIAL

Author

Veronika Logovinsky, Jinping Wang, Robert Lai, Andrew Satlin, Hans Basun, Lars Lannfelt, Martin Rabe, Lu Xu, Robert Gordon, June Kaplow, and Chad J. Swanson

Subjects
education.field_of_study, Pediatrics, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Population, Disease, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, business, education
Published
2014
Full Text
View/download PDF

7. F4‐03‐01: POPULATION CHARACTERIZATION IN THE EARLY STAGES OF ALZHEIMER'S DISEASE

Author

Gerald Novak, Ira Do, Martin Rabe, Nandini Raghavan, Lyn Harper-Mozley, Alette M. Wessels, Julie Chandler, Per Johan Luthman, and Veronika Logovinsky

Subjects
Genetics, education.field_of_study, Epidemiology, business.industry, Health Policy, Population, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, education, business
Published
2014
Full Text
View/download PDF

8. F4‐03‐04: RETROFITTING EXISTING TOOLS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM

Author

Nandini Raghavan, Veronika Logovinsky, Peter Castelluccio, Peng Yu, Alette M. Wessels, Scott W. Andersen, and Zongjun Zhang

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Risk analysis (engineering), Epidemiology, business.industry, Health Policy, Disease spectrum, Medicine, Retrofitting, Neurology (clinical), Geriatrics and Gerontology, business
Published
2014
Full Text
View/download PDF

9. P4‐181: INITIAL LEARNINGS FROM SCREENING STRATEGIES IN THE BAN 2401‐G000‐201 TRIAL: AN EARLY ALZHEIMER'S DISEASE STUDY

Author

Jinping Wang, Ira Do, Andrew Satlin, Robert Gordon, June Kaplow, Veronika Logovinsky, Lu Xu, Martin Rabe, Hans Basun, Lars Lannfelt, Chad J. Swanson, and Robert Lai

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Alternative medicine, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Physical therapy, Medicine, Neurology (clinical), Geriatrics and Gerontology, business, Intensive care medicine
Published
2014
Full Text
View/download PDF

10. P1–398: Designing the next generation of disease modification trials in people with early Alzheimer's disease: Learnings from recently completed programs in mild‐to‐moderate populations

Author

Veronika Logovinsky, Suna Barlas, Steven G. Potkin, Eric Siemers, Amir H Kalali, Steven J. Romano, and Reisa A. Sperling

Subjects
Gerontology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Alternative medicine, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Disease modification, Medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2013
Full Text
View/download PDF

11. P4–281: Microglial involvement and amyloid reduction with BAN2401/mAb158, a monoclonal antibody with high selectivity for protofibrils: In vitro and ex vivo analyses

Author

Robert Lai, Andrew Satlin, June Kaplow, Joseph Rogers, Diego Mastroeni, Akhiko Koyama, Bradford A. Navia, Barbara Biscaro, Veronika Logovinsky, Christer Möller, Namita Kumar, Chad J. Swanson, Galina Kusnetov, and Lars Lannfelt

Subjects
Amyloid, Epidemiology, medicine.drug_class, Chemistry, Health Policy, High selectivity, Monoclonal antibody, Molecular biology, In vitro, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, Neurology (clinical), Geriatrics and Gerontology, Ex vivo
Published
2013
Full Text
View/download PDF

12. P4–282: A multimodal imaging study of mAb158, a murine monoclonal antibody with high selectivity for amyloid protofibrils, in Tg2576 mice

Author

Christer Möller, Stephen Krause, Paul J. McCracken, Lars Lannfelt, Robert Lai, Andrew Satlin, Chad J. Swanson, Bradford A. Navia, Ben Gershman, Veronika Logovinsky, Tyler Teceno, June Kaplow, Akihiko Koyama, and Carlos Perdomo

Subjects
Multimodal imaging, Amyloid, Epidemiology, business.industry, Health Policy, High selectivity, Molecular biology, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, Murine monoclonal antibody, business
Published
2013
Full Text
View/download PDF

13. O4–05–01: A first‐in‐human study of BAN2401, a novel monoclonal antibody against beta‐amyloid protofibrils

Author

Veronika Logovinsky, Andrew Satlin, Bradford A. Navia, Chad J. Swanson, Christer Möller, Robert Lai, Kenan Gu, Lars Lannfelt, Yanke Yu, and June Kaplow

Subjects
Amyloid, Epidemiology, business.industry, medicine.drug_class, Health Policy, First in human, Monoclonal antibody, Molecular biology, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, Beta (finance), business
Published
2013
Full Text
View/download PDF

14. P4–286: Pharmacology of BAN2401: A monoclonal antibody selective for beta‐amyloid protofibrils

Author

Chad J. Swanson, June Kaplow, Diego Mastroeni, Lars Lannfelt, Robert Lai, Erik Rollman Waara, Veronika Logovinsky, Christer Möller, Andrew Satlin, Joseph Rogers, and Bradford A. Navia

Subjects
Amyloid, Epidemiology, medicine.drug_class, Chemistry, Health Policy, Pharmacology, Monoclonal antibody, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, Neurology (clinical), Geriatrics and Gerontology, Beta (finance)
Published
2013
Full Text
View/download PDF

15. P4‐305: Introducing a new tool for optimizing responsiveness to decline in early Alzheimer's disease

Author

Suzanne Hendrix, Andrew Satlin, Veronika Logovinsky, Carlos Perdomo, and Jinping Wang

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, medicine.medical_specialty, Developmental Neuroscience, Epidemiology, business.industry, Health Policy, medicine, Neurology (clinical), Disease, Geriatrics and Gerontology, Intensive care medicine, business
Published
2012
Full Text
View/download PDF

16. P3‐415: E2012, a novel gamma‐secretase modulator, decreases plasma amyloid‐beta (Aβ) levels in humans

Author

Akira Ishibashi, Bhaskar Rege, Christa Nagy, Veronika Logovinsky, Yosuke Nakatani, and Edgar Schuck

Subjects
medicine.medical_specialty, biology, Epidemiology, Amyloid beta, Chemistry, Health Policy, Healthy subjects, Cmax, Matrix (biology), Psychiatry and Mental health, Cellular and Molecular Neuroscience, Endocrinology, Developmental Neuroscience, Internal medicine, medicine, biology.protein, Neurology (clinical), Geriatrics and Gerontology, Gamma secretase
Abstract

Results: E2012 reduced plasma Aβ40 and Aβ42 in healthy subjects in a dose-related manner. Aβ42 decreased to a greater extent than Aβ40 (maximum reductions at 400 mg ~ 50% and ~30%, respectively) at 4-6 hrs post-dose, without a rebound effect. AUC0-inf increased proportionally up to 400 mg. Cmax increased proportionally up to 200 mg and less than proportionally thereafter. Results from rat studies with E2012 were predictive of the results obtained in humans for plasma Aβ effect over 24 hr. Effects on rat CSF and brain Aβ followed similar trends, supporting the use of CSF as a surrogate matrix for effects on brain Aβ in humans.

Published
2010
Full Text
View/download PDF

17. P1‐167: Modeling conversion to dementia of the Alzheimer's type in a study of mild cognitive impairment

Author

Margaret Moline, Timothy Hsu, Stephen W. Hurt, Veronika Logovinsky, and Qin Wang

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Audiology, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, business, Cognitive impairment
Published
2008
Full Text
View/download PDF

18. Can we prevent Alzheimer's disease? Secondary 'prevention' trials in Alzheimer's disease

Author

H. Robert Brashear, Ara S. Khachaturian, Reisa A. Sperling, Dean M. Hartley, Veronika Logovinsky, J. Michael Ryan, Ronald C. Petersen, Maria C. Carrillo, Howard Feldman, Eric Siemers, and Susan Abushakra

Subjects
Secondary prevention, Clinical Trials as Topic, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, MEDLINE, Disease, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Alzheimer Disease, Primary prevention, Secondary Prevention, medicine, Humans, Dementia, Neurology (clinical), Geriatrics and Gerontology, Psychiatry, business
Abstract

Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possible. Current research and recently revised criteria for the diagnosis of AD by the National Institutes on Aging and the Alzheimer's Association suggest a continuum of disease from preclinical asymptomatic to symptomatic Alzheimer's dementia. In light of these revised criteria, the possibility of secondary prevention and even primary prevention is under discussion. The Alzheimer's Association Research Roundtable convened a meeting to discuss the rationale and feasibility of conducting secondary prevention trials in AD.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results